Manuscripts

General

1. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology.2008 Aug;115(8):1366-71, 1371.e1 (Published).
(Manuscript) |  View Publication   
 
2. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: what is focal and what is diffuse?. Am J Ophthalmol.2008 Nov;146(5):649-55.e1-6. (Published).
(Manuscript) |  View Publication   
 
3. Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of optical coherence tomography in diabetic macular edema, with and without reading center manual grading from a clinical trials perspective. Invest Ophthalmol Vis Sci.2009 Feb;50(2):560-6 (Published).
(Manuscript) |  View Publication   
 
4. Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual Acuity in diabetic patients. Invest Ophthalmol Vis Sci.2009 Apr;50(4):1580-4. (Published).
(Manuscript) |  View Publication   
 
5. Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network. The Risk of Endophthalmitis Following Intravitreal Injection in the DRCR.net Laser-Ranibizumab-Triamcinolone Clinical Trials. Arch Ophthalmol. 2009 Dec;127(12):1581-3 (Published).
(Manuscript) |  View Publication   
 
6. Ferris FL, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of ocular coherence tomography data for use in clinical research. Ophthalmology 2010 Aug;117:1512–1516 (Published).
(Manuscript) |  View Publication   
 
7. Sun JK, Aiello LP, Cavallerano JD, Stockman M, Miller KM, Qin H, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Visual acuity testing using autorefraction or pinhole as compared with manual DRCR protocol refraction in individuals with diabetes. Ophthalmology.2011 Mar;118:537–542 (Published).
(Manuscript) |  View Publication   
 
8. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, for the Diabetic Retinopathy Clinical Research Network. Comparison of Film and Digital Fundus Photographs in Eyes of Individuals with Diabetes Mellitus. IOVS 2011 Aug;52:6168-73 (Published).
(Manuscript) |  View Publication   
 
9. Bhavsar AR, Stockdale CR, Ferris FL III, Brucker AJ, Bressler NM, Glassman AR, for the Diabetic Retinopathy Clinical Research. Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics. Arch Ophthalmol. 2012 Jun;130(6):809-810 (Published).
(Manuscript) |  View Publication   
 
10. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA. 2014 Jun 11;311(22):2269-70 (Published).
(Manuscript) |  View Publication   
 
11. Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intavitreous injections and the importance of using povidone-iodine: Update from the Diabetic Retinopathy Clinical Research Network. Jama Ophthal.2016 August. doi:10.1001/jamaophthalmol.2016.2741 (Published).
(Manuscript) |  View Publication   
 

Protocol A - Laser Photocoagulation for Diabetic Macular Edema

1. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology.2007 Mar;114(3):525-36 (Published).
(Manuscript) |  View Publication   
 
2. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol.2007 Apr;125(4):469-80 (Published).
(Manuscript) |  View Publication   
 
3. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci.2008 May;49(5):1745-52 (Published).
(Manuscript) |  View Publication   
 
4. Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina.2009 Mar;29(3):300-5 (Published).
(Manuscript) |  View Publication   
 
5. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H; Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina 2009 May;29(5):613-7 (Published).
(Manuscript) |  View Publication   
 
6. Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; Diabetic Retinopathy Clinical Research Network. Association of fluorescein angiographic features with visual acuity and with OCT and stereoscopic color fundus photographic features of DME in a randomized clinical trial. Retina.2010 Dec;30(10):1627-37 (Published).
(Manuscript) |  View Publication   
 

Protocol AA - UWF Risk of DR Worsening Over Time

1. Aiello LP, Odia I, Glassman AR, Melia M, Jampol LM, Bressler NM, Kiss S, Silva PS, Wykoff CC, Sun JK, for the Diabetic Retinopathy Clinical Research Network. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthal. 2018. In-Press (In-Press).
(Manuscript)   
 

Protocol B - Intravitreal Triamcinolone Acetonide versus Laser Study

1. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol.2007 Sep;144(3):454-6 (Published).
(Manuscript) |  View Publication   
 
2. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina.2008 Jul-Aug;28(7):919-30 (Published).
(Manuscript) |  View Publication   
 
3. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology.2008 Sep;115(9):1447-9.e1-10 (Published).
(Manuscript) |  View Publication   
 
4. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51 (Published).
(Manuscript) |  View Publication   
 
5. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009 Dec;127(12):1566-71 (Published).
(Manuscript) |  View Publication   
 
6. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS, Miller KM, for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010 May;117(5):946-953 (Published).
(Manuscript) |  View Publication   
 
7. Lauer AK, Bressler NM, Edwards AR, for the Diabetic Retinopathy Clinical Research Network. Frequency of Intraocular Pressure Increase within Days After Intravitreal Triamcinolone Injections in the Diabetic Retinopathy Clinical Research Network. Arch Ophthalmol. 2011 Aug;129(8):1097-1099. (Published).
(Manuscript) |  View Publication   
 

Protocol C - OCT Diurnal Variation Study

1. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol.2006 Dec;124(12):1701-7 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology.2007 Aug;114(8):1520-5 (Published).
(Manuscript) |  View Publication   
 

Protocol D - Vitrectomy Study

1. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net, Haller JA, Qin H, Apte RS, Beck RW, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010 Jun;117:1087-1093.e3 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. Retina. 2010 Oct;30(9):1488-95 (Published).
(Manuscript) |  View Publication   
 

Protocol E - Peribulbar Triamcinolone Acetonide Study

1. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, Bressler N, Browning D, Danis R, Fan J, Flaxel C, Friedman S, Glassman A, Kollman C, Lazarus H.. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology.2007 Jun;114(6):1190-6 (Published).
(Manuscript) |  View Publication   
 
2. Chew EY, Glassman AR, Beck RW, Bressler NM, Fish GE, Ferris FL, Kinyoun JL; Diabetic Retinopathy Clinical Research Network. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina. 2011 Feb;31(2):284-9 (Published).
(Manuscript) |  View Publication   
 

Protocol F - PRP Study

1. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol.2009 Feb;127(2):132-40 (Published).
(Manuscript) |  View Publication   
 

Protocol G - Subclinical Diabetic Macular Edema Study

1. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol.2008 May;145(5):894-901 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network. Observational Study of Subclinical Diabetic Macular Edema. Eye (Lond). 2012 Jun;26(6):900-1 (Published).
(Manuscript) |  View Publication   
 

Protocol H - Bevacizumab (Avastin) Phase 2 Study

1. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology.2007 Oct;114(10):1860-7 (Published).
(Manuscript) |  View Publication   
 
2. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina.2008 Jan;28(1):36-40 (Published).
(Manuscript) |  View Publication   
 

Protocol I - Laser-Ranibizumab-Triamcinolone for DME

1. Diabetic Retinopathy Clinical Research Network. Expanded 2-year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011 Apr;118(4):609-14. (Published).
(Manuscript) |  View Publication   
 
2. The Diabetic Retinopathy Clinical Research Network. Rationale for the Diabetic Retinopathy Clinical Research Network Intravitreal Anti-VEGF Treatment and Follow-up Protocol for Center-involved Diabetic Macular Edema. Ophthalmology. 2011 Dec;118:e5-e14 (Published).
(Manuscript) |  View Publication   
 
3. Glassman AR, Stockdale CR, Beck RW, Baker C, Bressler NM; for the Diabetic Retinopathy Clinical Research Network. Evaluation of Masking Study Participants to Intravitreal Injections in a Randomized Clinical Trial. Arch Ophthalmol. 2012 Feb;130(2):190-194 (Published).
(Manuscript) |  View Publication   
 
4. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 June;117(6):1064-1077.e35 (Published).
(Manuscript) |  View Publication   
 
5. Bressler S, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA, for the Diabetic Retinopathy Clinical Research Network. Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema with Ranibizumab. Arch Ophthalmol. 2012 Sep;130(9):1153-1161 (Published).
(Manuscript) |  View Publication   
 
6. The Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL III, Glassman AR, Maturi RK, Melia M. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year Randomized Trial Results. Ophthalmology 2012;119:2312–18 (Published).
(Manuscript) |  View Publication   
 
7. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Stone T, for the Diabetic Retinopathy Clinical Research Network. Exploratory Analysis of Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. JAMA Ophthalmol. 2013; 131(8):1033-1040 (Published).
(Manuscript) |  View Publication   
 
8. Bressler SB, Almukhtar T, Aiello LP, Bressler NM, Ferris FL III, Glassman AR, Greven CM, for the Diabetic Retinopathy Clinical Research Network. Green or Yellow Laser Treatment for Diabetic Macular Edema: Exploratory Assessment within the Diabetic Retinopathy Clinical Research Network. Retina. 2013 Nov-Dec;33(10):2080-8. (Published).
(Manuscript) |  View Publication   
 
9. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW; Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology. 2015 Feb;122(2):375-81. doi: 10.1016/j.ophtha.2014.08.047. Epub 2014 Oct 28. (Published).
(Manuscript) |  View Publication   
 
10. Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang S, Jampol LM, Kim JE, Melia M, for the Diabetic Retinopathy Clinical Research Network. Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained IOP Elevation or Ocular Hypotensive Treatment. JAMA Ophthalmol. JAMA Ophthalmol. 2015 May 1;133(5):589-97. doi:10.1001/jamaophthalmol.2015.186 (Published).
(Manuscript) |  View Publication   
 
11. Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, for the Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy. Retina. 2015 Dec;35(12):2516-28. doi: 10.1097/IAE.0000000000000617 (Published).
(Manuscript) |  View Publication   
 
12. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME, for the Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016 Mar 1;134(3):278-85. doi: 10.1001/jamaophthalmol.2015.5346 (Published).
(Manuscript) |  View Publication   
 
13. Diabetic Retinopathy Clinical Research Network. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol. 2016 Apr;164:57-68. doi: 10.1016/j.ajo.2015.12.025. Epub 2016 Jan 21. (Published).
(Manuscript) |  View Publication   
 
14. BressleR SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, Jampol LM, Maguire M, Melia M, for the Diabetic Retinopathy Clinical Research Network. Changes in Diabetic Retinopathy Severity When Treating Diabetic Macular Edema with Ranibizumab: DRCR.net Protocl I 5-Year Report. Retina.OCT 2018;38(10):1896-1904 (Published).
(Manuscript)   
 

Protocol J - Laser-Ranibizumab-Triamcinolone for DME Plus PRP

1. Diabetic Retinopathy Clinical Research Network. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema Following Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina. 2011 June;31(6):1009-27 (Published).
(Manuscript) |  View Publication   
 

Protocol K - Laser Response

1. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. Retina.2009 Nov-Dec;29(10):1436-43 (Published).
(Manuscript) |  View Publication   
 

Protocol L - Autorefraction and VA Reproducibility Study

1. The Diabetic Retinopathy Clinical Research Network. Evaluation of Visual Acuity Measurements after Autorefraction versus Manual Refraction in Eyes with and without Diabetic Macular Edema. Arch Ophthalmol. 2012 Apr; 130:470-479 (Published).
(Manuscript) |  View Publication   
 

Protocol M - Diabetes Education Study

1. Diabetic Retinopathy Clinical Research Network. Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2015 Aug;133(8):888-96. doi: 10.1001/jamaophthalmol.2015.1312. (Published).
(Manuscript) |  View Publication   
 

Protocol N - Intravitreal Ranibizumab for Vitreous Hemorrhage from PDR Study

1. Diabetic Retinopathy Clinical Research Network. Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2013 Mar 1;131(3):283-93. doi: 10.1001/jamaophthalmol.2013.2015. (Published).
(Manuscript) |  View Publication   
 
2. Bhavsar AR, Torres K, Bressler NM, Glassman AR, Jampol LM, Kinyoun JL, for the Diabetic Retinopathy Clinical Research Network. Evaluation of Results 1 Year Following Use of Short-Term Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. JAMA Ophthalmol. July 2014;132(7):889-890 (Published).
(Manuscript) |  View Publication   
 

Protocol O - TD/SD OCT Comparison and Reproducibility

1. Diabetic Retinopathy Clinical Research Network. Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography. IOVS December 2012 53:8154-8161 (Published).
(Manuscript) |  View Publication   
 
2. Diabetic Retinopathy Clinical Research Network Writing Committee. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol. 2014 Sep;132(9):1113-22. doi: 10.1001/jamaophthalmol.2014.1698 (Published).
(Manuscript) |  View Publication   
 
3. Susan B. Bressler, Allison R. Edwards, Christopher M. Andreoli, Paul Andrew Edwards, Adam R. Glassman, Glenn J. Jaffe, Michele Melia, Jennifer K. Sun, and for the Diabetic Retinopathy Clinical Research Network/Writing Committee. Reproducibility of Optovue RTVue Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Zeiss Stratus Metrics in Diabetic Macular Edema. Trans. Vis. Sci. Tech.: January/February 2015, Vol. 4, No. 1. doi: http://dx.doi.org/10.1167/tvst.4.1.5 (Published).
(Manuscript) |  View Publication   
 

Protocol P - Cataract Surgery with Center-Involved DME Study

1. Diabetic Retinopathy Clinical Research Network. Pilot Study of Individuals with Diabetic Macular Edema Undergoing Cataract Surgery. JAMA Ophthalmol. 2014 Feb 1;132(2):224-6. (Published).
(Manuscript) |  View Publication   
 

Protocol Q - Cataract Surgery without Center-Involved DME Study

1. Diabetic Retinopathy Clinical Research Network. Writing Committee: Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, Kim SJ, Murtha TJ, Rauser ME, Stockdale C.. Macular Edema After Cataract Surgery In Eyes Without Pre-operative Central-involved Diabetic Macular Edema. JAMA Ophthalmol. 2013 Jul;131(7):870-9. (Published).
(Manuscript) |  View Publication   
 

Protocol R - Phase II non-Central DME NSAID Study

1. Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M, Diabetic Retinopathy Clinical Research Network. Topical Nepafenec in Eyes with Non-Central Diabetic Macular Edema. Retina. 2015 May;35(5):944-56. doi: 10.1097/IAE.0000000000000403 (Published).
(Manuscript) |  View Publication   
 

Protocol S - Prompt PRP vs Ranibizumab+Deferred PRP for PDR Study

1. Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Trial. JAMA. 2015; 314(20):2137-2146. doi: 10.1001/jama.2015.15217 (Published).
(Manuscript) |  View Publication   
 
2. Gross JG, Glassman AR. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmol. 2016 Jan;134(1):13-4.DOI: 10.1001/jamaophthalmol.2015.5079 (Published).
(Manuscript)   
 
3. Gross JG, Glassman AR. Comment and Response, Panretinal Photocoagulation vs Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy: Author Reply. JAMA Ophthalmol.2016 June;134(6):715-16 (Published).
(Manuscript)   
 
4. Beaulieu WT, Bressler NM, Melia M, Owsley C, Mein CE, Gross JG, Jampol LM, Glassman AR, for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes from a Randomized Clinical Trial. Am J Ophthalmol. 2016 Oct;170:206-213. doi: 10.1016/j.ajo.2016.08.008. Epub 2016 Aug 12. (Published).
(Manuscript)   
 
5. Beaulieu WT, Bressler NM, Gross JG. Author Reply.Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Amer J Ophthal. 2017;177:223. DOI: http://dx.doi.org/10.1016/j.ajo.2017.02.010 (Published).
(Manuscript)   
 
6. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME, for the Diabetic Retinopathy Clinical Research Network. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. 2017 Apr;124(4):431-439. doi: 10.1016/j.ophtha.2016.12.005. (Published).
(Manuscript)   
 
7. Hutton DW, Stein JD, Bressler NM,Jampol LM, Browning D, Glassman AR, for the Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for PDR: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. JAMA Ophthalmol. 2017 Jun 1;135(6):576-584. doi: 10.1001/jamaophthalmol.2017.0837. (Published).
(Manuscript)   
 
8. Gross JG, Glassman AR, Klein MJ, Ferris FL, Bressler NM, Beck RW. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2017 Jun 1;135(6):672-673. doi: 10.1001/jamaophthalmol.2017.0969 (Published).
(Manuscript)   
 
9. Jampol LM, Odia I, Glassman AR, Baker CW, Bhorade AM, Han DP, Jaffe GJ, Melia M, Bressler NM, Tanna AP. Panretinal Photocoagulation vs Ranibizumab for Proliferative Diabetic Retinopathy: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. Retina. 2017 Nov 10. doi: 10.1097/IAE.0000000000001909. [Epub ahead of print] (Published).
(Manuscript)   
 
10. Bressler SB, Beaulieu WT, Glassman AR. Reply:Re: Bressler et al.: Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab (Ophthalmology. 2017;124:431-439). December 2017;124(12):e88–e89 (Published).
(Manuscript)   
 
11. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Melia M, Chen Eric, Pavlica MR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Factors accociated with vision and edema outcomes. Ophthalmology. 2018 Jul 3. pii: S0161-6420(18)30577-3. doi: 10.1016/j.ophtha.2018.04.039. (In-Press).
(Manuscript)   
 
12. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL, Gardner TW, Jampol LM, Martic DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol. Published online July 24, 2018. doi:10.1001/jamaophthalmol.2018.3255 (Published).
(Manuscript) |  View Publication   
 
13. Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Rationale and Application of the Protocol S Anti–Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2019 Jan; 126 (1): 87-95 (Published).
(Manuscript)  |  View Presentation  
 

Protocol T - Aflibercept, Bevacizumab and Ranibizumab Comparison for DME Study

1. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Mar 26; 372(13): 1193–1203. DOI: 10.1056/NEJMoa1414264 (Published).
(Manuscript) |  View Publication   
 
2. Wells JA, Glassman AR, Jampol LM. Targeting the Effect of VEGF in Diabetic Macular Edema: Author Reply. N Engl J Med 2015; 373:479-482.July 30, 2015.DOI: 10.1056/NEJMc1505684 (Published).
(Manuscript) |  View Publication   
 
3. Jampol LM, Glassman AR, Bressler NM. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015 Sep;133(9):983-4. doi: 10.1001/jamaophthalmol.2015.1880 (Published).
(Manuscript)   
 
4. Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR, for the Diabetic Retinopathy Clinical Research Network. Anti–Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016;134(12):1429-1434. doi:10.1001/jamaophthalmol.2016.3698 (Published).
(Manuscript) |  View Publication   
 
5. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. 2016;134(8):888-896. doi:10.1001/jamaophthalmol.2016.1669. (Published).
(Manuscript)   
 
6. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016;123(6):1351-9. doi.org/10.1016/j.ophtha.2016.02.022 (Published).
(Manuscript) |  View Publication   
 
7. Wells JA, Glassman AR, Ayala AR, Jampol LM. Author Reply. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Jan;124(1):e5-e6. doi: 10.1016/j.ophtha.2016.04.032. (Published).
(Manuscript)   
 
8. Bressler NM, Glassman AR, Hutton DW. Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply. JAMA Ophthalmol. 2017 Mar 1;135(3):291-292 (Published).
(Manuscript) |  View Publication   
 
9. John A. Wells, Adam R. Glassman, Lee M. Jampol, Lloyd Paul Aiello, Andrew N. Antoszyk, Carl W. Baker, Neil M. Bressler, David J. Browning, Crystal G. Connor, Michael J. Elman, Frederick L. Ferris, Scott M. Friedman, Michele Melia, Dante J. Pieramici, Jennifer K. Sun, Roy W. Beck, for the Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness with 1-year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599 (Published).
(Manuscript) |  View Publication   
 
10. John A. Wells, Adam R. Glassman, Lee M. Jampol, Allison Ayala, Neil M. Bressler. Author Reply. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Mar;124(3):e26-e27. http://dx.doi.org/10.1016/j.ophtha.2016.07.001 (Published).
(Manuscript)   
 
11. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821 (Published).
(Manuscript)   
 
12. Wells JA, Glassman AR, Bressler NM, Ayala AR, Jampol LM. Author Reply. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2017 Apr;124(4):e38-e39. doi: 10.1016/j.ophtha.2016.08.032. (Published).
(Manuscript)   
 
13. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved DME With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565. (Published).
(Manuscript)   
 
14. Glassman AR, Liu D, Jampol LM, Sun JK, for the Diabetic Retinopathy Clinical Research Network. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. IOVS.2018 Mar;59(3):1119-1205.doi:10.1167/iovs.17-22853 (Published).
(Manuscript) |  View Publication   
 
15. Jampol LM, Glassman AR, Liu D, Aiello L Paul, Bressler NM, Duh EJ,Quaggin S, Wells JA, Wykoff CC, for the Diabetic Retinopathy Clinical Research Network. Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema. Ophthalmology. 2018 Mar 7. pii: S0161-6420(17)32232-7. doi: 10.1016/j.ophtha.2018.01.019. [Epub ahead of print] (Published).
(Manuscript)   
 
16. Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, Gonzalez VH, Jampol LM, Melia M, Sun JK, Wells JA, for the Diabetic Retinopathy Clinical Research Network. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. Am J Ophthalmol. 2018 Aug 2. pii: S0002-9394(18)30413-6. doi: 10.1016/j.ajo.2018.07.030. [Epub ahead of print] (Published).
(Manuscript)   
 
17. Glassman AR, Duh EJ, Liu D, Jampol LM. Author Reply. Re. Du et al.: Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 Nov;125(11):e82. doi: 10.1016/j.ophtha.2018.05.004. (Published).
(Manuscript)   
 

Protocol U - Phase II Combination Steroid and Anti-VEGF for Persistent DME Study

1. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2017 Nov 11. doi: 10.1001/jamaophthalmol.2017.4914. [Epub ahead of print] (Published).
(Manuscript)  |  View Presentation